Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted Total Current Liabilities of $122.8 million for Q2 2026, down 17.42% on a QoQ basis from $148.7 million in Q1 2026, and down 3.38% year-over-year from $127.1 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Total Current Liabilities for 17 years, with the latest figure at $122.8 million in Q2 2026.
- On a quarterly basis, Total Current Liabilities fell 3.38% year-over-year to $122.8 million in Q2 2026; TTM through Jun 2026 was $122.8 million, a 3.38% decrease from a year earlier, with the FY2025 full-year figure at $132.2 million, down 18.6% from the prior year.
- Total Current Liabilities was $122.8 million for Q2 2026 at Emergent BioSolutions, down from $148.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.2 billion in Q4 2022, with the low at $111.9 million in Q1 2025.
- Average Total Current Liabilities over 5 years is $425.8 million, with a median of $256.8 million recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 387.84% in 2023, then plunged 82.24% in 2025.
- Over 5 years, Total Current Liabilities stood at $1.2 billion in 2022, then plunged by 47.0% to $651.3 million in 2023, then sank by 75.07% to $162.4 million in 2024, then declined by 18.6% to $132.2 million in 2025, then decreased by 7.11% to $122.8 million in 2026.
- The last three Total Current Liabilities figures came in at $122.8 million (Q2 2026), $148.7 million (Q1 2026), and $132.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 18.66 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 37.11 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 2.12 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 354.06 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 122.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 122.80 Mn |
| Mar 31, 2026 | 148.70 Mn |
| Dec 31, 2025 | 132.20 Mn |
| Sep 30, 2025 | 136.50 Mn |
| Jun 30, 2025 | 127.10 Mn |
| Mar 31, 2025 | 111.90 Mn |
| Dec 31, 2024 | 162.40 Mn |
| Sep 30, 2024 | 229.90 Mn |
| Jun 30, 2024 | 619.70 Mn |
| Mar 31, 2024 | 630.20 Mn |
| Dec 31, 2023 | 651.30 Mn |
| Sep 30, 2023 | 664.00 Mn |
| Jun 30, 2023 | 693.20 Mn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Sep 30, 2022 | 264.40 Mn |
| Jun 30, 2022 | 276.70 Mn |
| Mar 31, 2022 | 249.20 Mn |
| Dec 31, 2021 | 374.00 Mn |
| Sep 30, 2021 | 365.40 Mn |
API Access
Emergent BioSolutions Total Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "total-current-liabilities", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();